High bad and bcl-xL gene expression and combined bad, bcl-xL, bax and bcl-2 mRNA levels:: Molecular predictors for survival of stage 2 soft tissue sarcoma patients

被引:0
|
作者
Köhler, T
Würl, P
Meye, A
Lautenschläger, C
Bartel, F
Borchert, S
Bache, M
Schmidt, H
Holzhausen, HJ
Taubert, H
机构
[1] Univ Halle Wittenberg, Inst Pathol, D-06097 Halle An Der Saale, Germany
[2] Univ Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, Leipzig, Germany
[3] Univ Leipzig, Clin Surg 1, Leipzig, Germany
[4] Univ Halle Wittenberg, Inst Med Biometry & Informat, D-06097 Halle An Der Saale, Germany
[5] Univ Halle Wittenberg, Dept Radiotherapy, D-06097 Halle An Der Saale, Germany
[6] Univ Dresden, Urol Clin, Dresden, Germany
关键词
soft tissue sarcoma; prognostic markers; bad; bax; bcl-xL bcl-2; mRNA expression; quantitative; high-throughput RT-PCR; 5 ' nuclease assay; DNA-coated strips;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The role of the bcl-2 gene family members in promoting or antagonizing apoptosis in malignant tumors, including soft tissue sarcomas (STS), is well known. However, the impact of mRNA expression of bcl-2 family genes on prognosis has not been thoroughly investigated in STS. Samples from 82 STS patients were analyzed for mRNA expression of bad, bax, bcl-x(L) and bcl-2 by a high-throughput quantitative RTPCR approach, using validated assays based on TaqMan(R) technology. The mRNA data, related to glyceraldehyde-3-phosphate dehydrogenase expression measured in the same sample, were analysed for their correlation to tumor stage and overall survival of patients. In a Kaplan-Meier analysis none of the mRNA levels investigated differed significantly with regard to their impact on survival (log-rank test). However, after including the tumor stage in the statistical analysis, a borderline significance was observed for bad mRNA expression (p=0.068) indicating a stage-specific impact of mRNA expression on prognosis. Considering STS patients of tumor stage 2, multivariate Cox analysis revealed that bad mRNA values greater than or equal to10 (p=0.0039; RR=9.08), bcl-x(L) greater than or equal to1.5 (p=0.067; RR = 4.59), bax greater than or equal to0.005 (p=0.1; RR=2.84) and bcl-2 <3 (p=0.42; RR=1.7) were associated with a poor prognosis. Combined high bad/bcl-x(L) mRNA expression levels revealed a 20 fold increase in the relative risk of tumor-related death (p=0.016) when comparing the poor and good prognosis groups. There was a 14.5 fold and 6.5-fold increase in the risk for the combinations of high bax/bcl-x(L) mRNA (p=0.018) and bax/bcl-2 mRNA expression (p=0.017), respectively. In conclusion, high bad mRNA levels and combined values of bad/bcl-x(L), bax/bcl-x(L) and bax/bcl-2 appear to be independent prognostic factors at least for stage 2 STS patients. In the combinations of mRNA levels there was more than an additive effect pointing to different pathways of prognostic relevance.
引用
收藏
页码:1553 / 1559
页数:7
相关论文
共 50 条
  • [41] A Novel BCL-2/BCL-Xl Dual Inhibitor Overcomes Ibrutinib-Resistance Conferred By the Upregulation of Integrin Pathway and BCL-Xl
    Deng, Jing
    Mao, Tingting
    Huang, Xiaojing
    Rui, Li
    Wang, Guangfeng
    Fang, Douglas D.
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2019, 134
  • [42] Bcl-2 and Bcl-xL Suppress Glucose Signaling in Pancreatic β-Cells
    Luciani, Dan S.
    White, Sarah A.
    Widenmaier, Scott B.
    Saran, Varun V.
    Taghizadeh, Farnaz
    Hu, Xiaoke
    Allard, Michael F.
    Johnson, James D.
    DIABETES, 2013, 62 (01) : 170 - 182
  • [43] Studies leading to potent, dual inhibitors of bcl-2 and Bcl-xL
    Bruncko, Milan
    Oost, Thorsten K.
    Belli, Barbara A.
    Ding, Hong
    Joseph, Mary K.
    Kunzer, Aaron
    Martineau, Darlene
    McClellan, William J.
    Mitten, Michael
    ng, Shi-Chu Ng
    Nimmer, Paul M.
    Oltersdorf, Tilman
    Park, Cheol-Min
    Petros, Andrew M.
    Shoemaker, Alexander R.
    Song, Xiaohong
    Wang, Xilu
    Wendt, Michael D.
    Zhang, Haichao
    Fesik, Stephen W.
    Rosenberg, Saul H.
    Elmore, Steven W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (04) : 641 - 662
  • [44] Modulation of synaptic transmission by the BCL-2 family protein BCL-xL
    Jonas, EA
    Hoit, D
    Hickman, JA
    Brandt, TA
    Polster, BM
    Fannjiang, Y
    McCarthy, E
    Montanez, MK
    Hardwick, JM
    Kaczmarek, LK
    JOURNAL OF NEUROSCIENCE, 2003, 23 (23): : 8423 - 8431
  • [45] 慢性肝病中凋亡蛋白Bcl-2、Bcl-XL、Bcl-2α、Bax的调节作用
    陈乃玲
    邓涛
    陈佩兰
    李琳
    中华内科杂志, 2000, (12) : 15 - 17+72
  • [46] Immunohistochemical expression of Bcl-2, Bcl-xL, Bax, p53 proteins in gastric adenoma and adenocarcinoma
    Lee, D
    Han, S
    Baek, J
    Ahn, B
    Lee, E
    Chung, I
    Park, D
    GASTROENTEROLOGY, 2003, 124 (04) : A186 - A186
  • [47] Differential expression of Bcl-2, Bcl-XL and p53 in colorectal cancer
    Han, Hye Seung
    Park, Young-Mee
    Hwang, Tae Sook
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 (07) : 1108 - 1114
  • [48] bFGF对卵巢癌CAOV3细胞Bcl-2、Bcl-xl、Bax、Bad表达的影响
    叶丽平
    孙黎光
    张莹
    张尤新
    医学分子生物学杂志, 2007, (03) : 215 - 220
  • [49] BCL-2 and BCL-Xl Use Different Molecular Mechanisms to Regulate Carbohydrate Metabolism
    Dejean, Laurent
    Olea, Catalina
    Lopez, Itzel
    Filipp, Fabian
    Krishnan, Krish
    BIOPHYSICAL JOURNAL, 2021, 120 (03) : 261A - 261A
  • [50] Bel-xS and Bad potentiate the death suppressing activities of Bcl-xL, Bcl-2, and A1 in yeast
    Tao, Weikang
    Kurschner, Cornelia
    Morgan, James I.
    Journal of Biological Chemistry, 1998, 273 (37):